Identification of FDA-approved drugs that target hepatitis B virus transcription

Journal of Viral Hepatitis

Volumn 23, Issue 3, 2016, Pages 191-201

  Van De Klundert, M A A ^a,b   Zaaijer, H L ^a   Kootstra, N A ^b  

^a SANQUIN RESEARCH   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

antiviral therapy; drug screen; HBx; hepatitis B virus; transcription

Indexed keywords

ABAMECTIN; BENSERAZIDE; BEXAROTENE; BROMOCRIPTINE MESILATE; CALCIPOTRIOL; CAPSAICIN; CILNIDIPINE; CLODRONIC ACID; CROMOGLYCATE DISODIUM; DEXAMETHASONE; DIPYRIDAMOLE; ETIDRONIC ACID; FENOLDOPAM; FINASTERIDE; GLIPIZIDE; HYDROCORTISONE; ISOPRENALINE; LEVODOPA; LOMERIZINE; MELENGESTROL ACETATE; METHYLDOPA; NIFEDIPINE; NIMESULIDE; PHYSOSTIGMINE; TERBINAFINE; TRANILAST; TREQUINSIN; UNINDEXED DRUG; VIRUS PROTEIN; VIRUS RNA; ANTIVIRUS AGENT;

ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG APPROVAL; DRUG POTENCY; DRUG SCREENING; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; HEK293 CELL LINE; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; LUCIFERASE ASSAY; MTT ASSAY; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RNA TRANSCRIPTION; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS TRANSCRIPTION; CELL LINE; DRUG EFFECTS; DRUG REPOSITIONING; GENETIC TRANSCRIPTION; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; PRECLINICAL STUDY; PROCEDURES;

ANTIVIRAL AGENTS; CELL LINE; DRUG EVALUATION, PRECLINICAL; DRUG REPOSITIONING; HEPATITIS B VIRUS; HUMANS; MICROBIAL SENSITIVITY TESTS; TRANSCRIPTION, GENETIC; VIRUS REPLICATION;

EID: 84957428021     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12479     Document Type: Article

References (46)

1. Ott JJ, Stevens GA, Groeger J, Wiersma ST,. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012; 30 (12): 2212-2219.
2. Boni C, Fisicaro P, Valdatta C, et al,. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 2007; 81 (8): 4215-4225.
3. Das A, Hoare M, Davies N, et al,. Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection. J Exp Med 2008; 205 (9): 2111-2124.
4. Rehermann B, Lau D, Hoofnagle JH, Chisari FV,. Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J Clin Invest 1996; 97 (7): 1655-1665.
5. EASL clinical practice guidelines. Management of chronic hepatitis B virus infection. J Hepatol 2012; 57 (1): 167-185.
6. Lok AS, McMahon BJ,. Chronic hepatitis B: update 2009. Hepatology 2009; 50 (3): 661-662.
7. Sarri G, Westby M, Bermingham S, Hill-Cawthorne G, Thomas H,. Diagnosis and management of chronic hepatitis B in children, young people, and adults: of NICE guidance. BMJ 2013; 346: f3893.
8. Tang CM, Yau TO, Yu J,. Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments. World J Gastroenterol 2014; 20 (20): 6262-6278.
9. Belloni L, Allweiss L, Guerrieri F, et al,. IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest 2012; 122 (2): 529-537.
10. Liu F, Campagna M, Qi Y, et al,. Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes. PLoS Pathog 2013; 9 (9): e1003613.
11. Keasler VV, Hodgson AJ, Madden CR, Slagle BL,. Enhancement of hepatitis B virus replication by the regulatory X protein in vitro and in vivo. J Virol 2007; 81 (6): 2656-2662.
12. Lucifora J, Arzberger S, Durantel D, et al,. Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. J Hepatol 2011; 55 (5): 996-1003.
13. Tsuge M, Hiraga N, Akiyama R, et al,. HBx protein is indispensable for development of viraemia in human hepatocyte chimeric mice. J Gen Virol 2010; 91 (Pt 7): 1854-1864.
14. Zoulim F, Saputelli J, Seeger C,. Woodchuck hepatitis virus X protein is required for viral infection in vivo. J Virol 1994; 68 (3): 2026-2030.
15. Carmona S, Ely A, Crowther C, et al,. Effective inhibition of HBV replication in vivo by anti-HBx short hairpin RNAs. Mol Ther 2006; 13 (2): 411-421.
16. van de Klundert MA, van Hemert FJ, Zaaijer HL, Kootstra NA,. The hepatitis B virus x protein inhibits thymine DNA glycosylase initiated base excision repair. PLoS ONE 2012; 7 (11): e48940.
17. Baumert TF, Rogers SA, Hasegawa K, Liang TJ,. Two core promotor mutations identified in a hepatitis B virus strain associated with fulminant hepatitis result in enhanced viral replication. J Clin Invest 1996; 98 (10): 2268-2276.
18. Baumert TF, Marrone A, Vergalla J, Liang TJ,. Naturally occurring mutations define a novel function of the hepatitis B virus core promoter in core protein expression. J Virol 1998; 72 (8): 6785-6795.
19. Du J, Zhou Y, Fu QX, et al,. Bioluminescence imaging of hepatitis B virus enhancer and promoter activities in mice. FEBS Lett 2008; 582 (23-24): 3552-3556.
20. Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP,. GenePattern 2.0. Nat Genet 2006; 38 (5): 500-501.
21. Jansen L, Kootstra NA, van Dort KA, Takkenberg RB, Reesink HW, Zaaijer HL,. Hepatitis B virus pregenomic RNA is present in virions in plasma and is associated with a response to pegylated interferon alfa-2a and nucleos(t)ide analogues. J Infect Dis 2015; pii: jiv397. [Epub ahead of print].
22. Sells MA, Chen ML, Acs G,. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci USA 1987; 84 (4): 1005-1009.
23. Wu K, Gong Y, Zhang X, et al,. Inhibition of hepatitis B virus replication by recombinant small interfering RNAs. Acta Virol 2005; 49 (4): 235-241.
24. Wu KL, Zhang X, Zhang J, et al,. Inhibition of Hepatitis B virus gene expression by single and dual small interfering RNA treatment. Virus Res 2005; 112 (1-2): 100-107.
25. Dubiel JP, Kawecka-Jaszcz K, Kocemba J, et al,. Acute and long-term treatment of hypertension with nifedipine in the elderly. J Hum Hypertens 1990; 4 (4): 410-414.
26. Imai N, Konishi T, Serizawa M, Okabe T,. Do the effects of long-term lomerizine administration differ with age? Intern Med 2007; 46 (10): 683-684.
27. Deleu D, Northway MG, Hanssens Y,. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet 2002; 41 (4): 261-309.
28. Brodskii VY, Dubovaya TK, Zvezdina ND, Konchenko DS,. Mal'chenko LA. Dopamine disorganizes the rhythm of protein synthesis disrupting self-organization of hepatocytes in vitro. Bull Exp Biol Med 2013; 156 (1): 38-40.
29. Brodskii VY, Mal'chenko LA, Dubovaya TK, Konchenko DS, Zvezdina ND,. Administration of dopamine to rats disorganizes the rhythm of protein synthesis in hepatocytes. Bull Exp Biol Med 2014; 157 (2): 220-223.
30. Tang H, Delgermaa L, Huang F, et al,. The transcriptional transactivation function of HBx protein is important for its augmentation role in hepatitis B virus replication. J Virol 2005; 79 (9): 5548-5556.
31. Petranyi G, Ryder NS, Stutz A,. Allylamine derivatives: new class of synthetic antifungal agents inhibiting fungal squalene epoxidase. Science 1984; 224 (4654): 1239-1241.
32. Stutz A, Petranyi G,. Synthesis and antifungal activity of (E)-N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethanamine (SF 86-327) and related allylamine derivatives with enhanced oral activity. J Med Chem 1984; 27 (12): 1539-1543.
33. Chien MH, Lee TS, Kao C, Yang SF, Lee WS,. Terbinafine inhibits oral squamous cell carcinoma growth through anti-cancer cell proliferation and anti-angiogenesis. Mol Carcinog 2012; 51 (5): 389-399.
34. Kovarik JM, Mueller EA, Zehender H, Denouel J, Caplain H, Millerioux L,. Multiple-dose pharmacokinetics and distribution in tissue of terbinafine and metabolites. Antimicrob Agents Chemother 1995; 39 (12): 2738-2741.
35. Chapman SW, Pappas P, Kauffmann C, et al,. Comparative evaluation of the efficacy and safety of two doses of terbinafine (500 and 1000 mg day(-1)) in the treatment of cutaneous or lymphocutaneous sporotrichosis. Mycoses 2004; 47 (1-2): 62-68.
36. Hosseini-Yeganeh M, McLachlan AJ,. Tissue distribution of terbinafine in rats. J Pharm Sci 2001; 90 (11): 1817-1828.
37. Yan J, Wang X, Chen S,. Systematic review of severe acute liver injury caused by terbinafine. Int J Clin Pharm 2014; 36 (4): 679-683.
38. Kao WY, Su CW, Huang YS, et al,. Risk of oral antifungal agent-induced liver injury in Taiwanese. Br J Clin Pharmacol 2014; 77 (1): 180-189.
39. Savigni DL, O'Hare Doig RL, Szymanski CR, et al,. Three Ca2+ channel inhibitors in combination limit chronic secondary degeneration following neurotrauma. Neuropharmacology 2013; 75: 380-390.
40. Rosenbaum T, Gordon-Shaag A, Munari M, Gordon SE,. Ca2+/calmodulin modulates TRPV1 activation by capsaicin. J Gen Physiol 2004; 123 (1): 53-62.
41. Kazensky CA, Munson L, Seal US,. The effects of melengestrol acetate on the ovaries of captive wild felids. J Zoo Wildl Med 1998; 29 (1): 1-5.
42. Sica DA,. Centrally acting antihypertensive agents: an update. J Clin Hypertens (Greenwich) 2007; 9 (5): 399-405.
43. Clarke PB, Reuben M, el-Bizri H,. Blockade of nicotinic responses by physostigmine, tacrine and other cholinesterase inhibitors in rat striatum. Br J Pharmacol 1994; 111 (3): 695-702.
44. Whitaker RM, Wills LP, Stallons LJ, Schnellmann RG,. cGMP-selective phosphodiesterase inhibitors stimulate mitochondrial biogenesis and promote recovery from acute kidney injury. J Pharmacol Exp Ther 2013; 347 (3): 626-634.
45. Aritomi S, Konda T, Yoshimura M,. L/N-type calcium channel blocker suppresses reflex aldosterone production induced by antihypertensive action. Heart Vessels 2012; 27 (4): 419-423.
46. Guilhou JJ,. Calcipotriol. Ann Dermatol Venereol 2001; 128 (3 Pt 1): 229-237.